Dr.
Martin Bidlingmaier
Ludwig Maximilian’s University Munich, Germany
Dr.
Martin Bidlingmaier
Ludwig Maximilian’s University Munich, Germany
Dr. Bidlingmaier graduated from Ludwig Maximilian’s University Munich in 2000. He works in the Munich Pediatric Hemophilia Center (head: Prof. Dr. Karin Kurnik) at Dr. von Hauner’s Children’s University Hospital. He is board certified pediatrician and hemostasis specialist. He was appointed assistant professor of pediatrics and was head of the hospital’s emergency department.
In 2018 he joined the LMU Center for Development and Complex Chronic Diseases in Children (iSPZ Hauner) and established the hemostasis unit as part of the Munich Pediatric Hemophilia Center.
Additionally, he works as independent pediatrician in a private practice in Munich.
He is a member of national and international organizations and serves as secretary for the standing commission pediatrics of the German Society of Thrombosis and Hemostasis Research (GTH) since 2004. He is also a member of many groups and is Co-PI of the German Pediatric Hemophilia Research Database (GEPHARD).
His research interests include bleeding scores and perioperative care as well as pediatric thrombosis and hemophilia care.
Close
Dr.
Björn Dahlbäck
Lund University, Sweden
Dr.
Björn Dahlbäck
Lund University, Sweden
Björn Dahlbäck was born in Sweden. He attended Lund University where he earned his MD. He completed internship and residency at University Hospital in Malmö, Sweden. Johan Stenflo, a pioneer in blood coagulation research, served as his PhD mentor. This experience was crucial for his career as investigator of thrombotic and hemorrhagic diseases. He did postdoctoral research at Scripps in LaJolla with Hans Müller-Eberhard, a leading scientist in complement research, and later was Esther Z Greenberg visiting scholar at OMRF in Oklahoma. He is professor of Blood Coagulation Research at Lund University since 1989.
Dr. Dahlbäck is best known for his groundbreaking discovery of activated protein C (APC) resistance as the most common inherited risk factor of venous thrombosis. He showed APC resistance to be caused by a change in the FV gene, the mutation was subsequently identified by several groups and now referred to as FVLeiden. Another more recent breakthrough is the elucidation of a bleeding disorder called East Texas Bleeding. It is caused by a point mutation in the FV gene that activates a splice donor site that causes an in frame deletion of 702 amino acids from the B domain. The resulting FV-Short exposes a high affinity-binding site for TFPIa. The FV-TFPIa complex is retained in the circulation and causes the bleeding phenotype. Recently, he has shown that FV-Short and protein S are synergistic cofactors to TFPIa in inhibition of FXa. Other achievements include: first purification of human FV, discovery of the complex between protein S and the complement regulator C4BP, identification and cloning of the protein S-binding beta-chain of C4BP, electron microscopy visualization of the spider-like C4BP, sequencing and cloning of protein S, and the creation of Gas6 knockout mice. A noteworthy achievement outside the coagulation field is the identification of apoM, an HDL-associated apolipoprotein, and the discovery that it is the carrier of sphingosine 1- phosphate in blood.
In recognition of his research contributions, Dr Dahlbäck has received many honors and awards; the Louis Jeantet Prix de Medicine, the Göran Gustafsson’s prize, the Analytical Biochemistry Prize, the Werkö prize, the Söderberg Award, the Berend Houwen Award, the Ham-Wasserman lecture award and the William Dameshek Prize from ASH, Distinguished Career Award and Investigator Recognition Award from the ISTH and His Majesty the King’s medal. He is member of the Royal Swedish Academy of Science and honorary member of the ASH. He is presently Treasurer of the ISTH.
Close
Dr.
Christian Gachet
University Louis Pasteur of Strasbourg, France
Dr.
Christian Gachet
University Louis Pasteur of Strasbourg, France
Dr. Christian Gachet graduated as an MD (1985) and gained his PhD in Pharmacology (1991), at the University Louis Pasteur, Strasbourg, France. He is currently the Director of the INSERM Research Unit 1255 and the Director at Etablissement Français du Sang-Grand Est. Dr. Gachet general interest is in platelet physiology and pharmacology and in various topics related to transfusion medicine. Dr. Gachet has published over 300 papers in his area of expertise. He is recipient of the Biennial Award for Contributions to Haemostasis (ISTH, 2013, Amsterdam). He is corresponding member of the French National Academy of Medicine since 2018.
Close
Dr.
Andreas Greinacher
Universitätsmedizin Greifswald, Germany
Dr. Andreas Greinacher
Universitätsmedizin Greifswald, Germany
Andreas Greinacher, specialized for transfusion medicine, immunohematology and clinical immunology, is full professor and head of the department of transfusion medicine at the Universitätsmedizin Greifswald. His research interests are hereditary and immune mediated thrombocytopenias, especially heparin-induced thrombocytopenia and application of biophysics to understand molecular mechanisms of antigenicity of endogenous proteins. He has published more than 400 papers on these topics.
Close
Dr.
Berend Isermann
University of Leipzig, Germany
Dr.
Berend Isermann
University of Leipzig, Germany
Berend Isermann studierte Medizin in Würzburg, Bristol (Großbritannien) und New Haven, CT, USA. Nach dem AiP (Universitätsklinik Heidelberg) forschte er 5 Jahre in Milwaukee, WI, USA am Blood Research Institute. Zurück in Heidelberg erlangte er die Facharztausbildungen für Innere Medizin, Endokrinologie und Labormedizin sowie die Zusatzbezeichnungen Diabetologe (DDG) und Klinischer Chemiker (DGKL). 2011 erhielt er den Ruf auf die W3 Professur für Laboratoriumsmedizin und Klinische Chemie der Universität in Magdeburg, 2019 den Ruf auf die W3 Professur für Laboratoriumsmedizin und Klinische Chemie der Universität Leipzig. Von 2015 bis 2018 war er Vorstandsmitglied der DGKL, deren Präsident er 2017/2018 war.
Close
Dr.
Steffen Koschmieder
Aachen University, Germany
Dr. Steffen Koschmieder
Aachen University, Germany
Professor Dr. med. Steffen Koschmieder is board-certified in Internal Medicine, Hematology/Oncology, and Hemostaseology. He studied Medicine in Bochum and Mainz, Dijon, Houston, and Salt Lake City and received his specialty training in Frankfurt and Münster and was a postdoctoral researcher in Prof. Daniel Tenen´s laboratory at the Harvard Institutes of Medicine in Boston. He is currently professor for “Translational Hematology and Oncology” at RWTH Aachen University as well as Attending Physician, Head of Research, Head of the Clinical Laboratory of Molecular Hematolology, and Head of the Clinical Hemostasis in the Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation in Aachen. Prof. Koschmieder´s main interests are Myeloproliferative Neoplasms (MPN) and disorders of hemostasis and blood coagulation.
Close
Dr.
Karl J. Lackner
University Medical Center Mainz, Germany
Dr.
Karl J. Lackner
University Medical Center Mainz, Germany
Dr. Lackner graduated from medical school in Heidelberg, Germany in 1982. After 2 ½ years as post-doc at the NIH in Bethesda, Maryland, USA he began his residency in internal medicine at the university hospital in Heidelberg in 1985. He was board certified in internal medicine and cardiology in 1991. Thereafter, he moved as chief attending physician to the Institute of Clinical Chemistry and Laboratory Medicine of the University of Regensburg. In 1995 he was board certified in laboratory medicine. In 2001 he was appointed full professor and director of the Institute of Clinical Chemistry and Laboratory Medicine of the University Medical Center Mainz. From 2008 to 2010 and from 2012 to 2014 he served as deputy chief medical officer of the University Medical Center.
Dr. Lackner’s research focus is on cardiovascular disease and haemostaseology. Furthermore his laboratory is involved in the development of laboratory diagnostics. From 2002 to 2004 and again from 2008 to 2016 he was member of the review board medicine of the German Research Foundation. Between 2007 and 2011 he served as president of the German Society of Clinical Chemistry and Laboratory Medicine. Since 2008 he is associate editor of Clinical Chemistry and Laboratory Medicine.
Close
Dr.
Edelgard Lindhoff-Last
Cardioangiology Center Bethanien of Frankfurt, Germany
Dr.
Edelgard Lindhoff-Last
Cardioangiology Center Bethanien of Frankfurt, Germany
Edelgard Lindhoff-Last became Head of the Coagulation Research Center and of the Coagulation Center at the Cardioangiology Center Bethanien in January 2015, where she works as a specialist in internal medicine, focusing on angiology and haemostasis.
Prior to this appointment, Prof. Lindhoff-Last spent her career at Johann-Wolfgang Goethe-University, Frankfurt, Germany, beginning as a physician in 1987 and progressing to Fellow, Consultant, and Associate Professor, before becoming Professor of Angiology and Haemostaseology in 2008.
From 2004–2014 she was head of the department of Angiology and Haemostaseology at the Johann-Wolfgang Goethe University Hospital, Frankfurt, Germany. During her career, she has amassed 18 years of experience in clinical trials and – in addition to her clinical and scientific work – was responsible for the coagulation laboratory.
Prof. Lindhoff-Last is a member of the board of directors of the Gesellschaft für Thrombose- und Hämostaseforschung (GTH; Society of Thrombosis and Hemostasis Research), a member of the International Society of Thrombosis and Haemostasis (ISTH), and a board member of the ISTH subcommittee Control of Anticoagulation. She is also a member of the German societies of Angiology, Internal Medicine, Cardiology and the European Society of Cardiology.Her many research interests include monitoring of direct oral anticoagulants and their influence on coagulation assays ex vivo as well as documentation of bleeding management in anticoagulated patients in prospective registries or improving thrombophilia testing.
Close
Dr.
Götz Thomalla
University Medical Center Hamburg-Eppendorf, Germany
Dr. Götz Thomalla
University Medical Center Hamburg-Eppendorf, Germany
Götz Thomalla, MD, is professor for imaging based clinical stroke research, assistant medical director and head of the stroke team at the department of neurology at the University Medical Center Hamburg-Eppendorf. His key research areas are advanced brain imaging to study the pathophysiology of cerebral ischemia, clinical trials of acute stroke treatment, and brain network reorganization in cerebrovascular disease. He was coordinating investigator of the EU-funded WAKE-UP trial and is the neurological principal investigator of the TENSION study. He is Fellow of the European Stroke Association (ESO) and member of guideline groups of the German Neurological Society and ESO.
Close
Dr.
Mathias Uhlen
KTH Royal Institute of Technology and Karolinska Institutet Stockholm, Sweden
Dr. Mathias Uhlen
KTH Royal Institute of Technology and Karolinska Institutet Stockholm, Sweden
Mathias Uhlen’s research is focused on protein science, antibody engineering and precision medicine and ranges from basic research in human and microbial biology to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. His research has resulted in more than 550 publications and he is co-founder of 20 biotech companies. Since 2003, he has led an international effort to systematically map the human proteome and transcriptome to create a Human Protein Atlas using antibodies and various omics technologies. This effort has so far resulted the Tissue Atlas (2015) showing the distribution of proteins across human tissues and organs, the Cell Atlas (2016) showing the subcellular location of human proteins in single cells and the Pathology Atlas (2017) showing how cancer patient survival is tied to RNA and protein levels. He is member of the National Academy of Engineering (NAE) in USA, the Royal Swedish Academy of Science (KVA), the Swedish Academy of Engineering Science (IVA) and the European Molecular Biology Organization (EMBO). He is the President of the European Federation of Biotechnology and is chairing the International Working Group for Antibody Validation (IWGAV). From 2010-2015, he was the founding Director of the Science for Life Laboratory (SciLifeLab) which is a Swedish national center for molecular bioscience.
Close